NewSpring’s Fourth Growth Equity Healthcare Fund Exceeds Its Target, Raising over $180 Million

NewSpring, a family of private equity strategies investing in the lower-middle market, announces the final close of its oversubscribed fourth healthcare fund, NewSpring Health Capital IV (“NSH IV”), raising over $180 million. NewSpring Healthcare is a thesis-driven, domain-specific growth equity strategy, with over 20 years of experience investing in companies that help different segments of the healthcare ecosystem transform the way care is delivered to patients. NSH IV received strong support from existing and new investors, which include a diverse group of strategics, financial institutions, and family offices. Triago acted as exclusive placement agent for NSH IV.

“We partner with companies that influence healthcare by using technology and human capital in novel ways. Like our team, the management teams we invest behind are passionate about easing access to care, improving outcomes, and increasing efficiency while lowering costs.”

NSH IV will continue NewSpring Healthcare’s decades-long history by investing in companies that evolve and shape high-impact sectors in healthcare.

The NewSpring Healthcare team focuses on proprietary deal flow, using primary and secondary research to identify sectors that have a meaningful influence on healthcare. NSH IV has already made six investments prior to the final close, including specialized pharmaceutical distribution services provider, AeroSafe Global; end-to-end sleep disorders management provider, BetterNight; cardiovascular staffing leader, Healthworks; mobile dysphagia diagnostics leader, Patheous Health; provider of business process outsourcing services to behavioral health programs, Prosperity Behavior Health; and industry leader in healthcare disclosure management technology and services, Verisma.

"The NewSpring Healthcare team has extensive expertise in different segments of healthcare. We rely on this experience and our networks to influence the way we deploy capital. Our LPs recognized this differentiating factor, and we are deeply grateful for their support in what proved to be a successful fundraise in less-than-ideal macroeconomic circumstances."

Led by Dr. Kapila Ratnam, Mike Kaplan, and Brian Murphy, it’s that deep domain experience and passion for the sector that better positions the NewSpring Healthcare team to execute on strategic opportunities to help management teams grow their companies. A team of advisory partners round out the strategy’s healthcare industry expertise, including Pete Buzy, former CEO of previous NewSpring portfolio company Paragon Bioservices; Chris Bodine, former President of CVS Caremark; Bruce Downey, former Chairman and CEO of Barr Pharmaceuticals, Inc.; and Mark Pacala, a 30-year healthcare industry veteran.

With NewSpring Healthcare’s deep and growing deal pipeline of innovative healthcare companies, the strategy will continue to capitalize on the escalating opportunities and growing momentum within this segment of the market. NewSpring Healthcare invests from $10 to $25 million in lower-middle market companies that have between $10 to $100 million in revenue at the time of investment.